Coagulent Therapeutics

Leveraging 100+ years of collective experience and leveraging assets including over 30 patents acquired from Bayer AG and Maxygen, Coagulant Therapeutics has developed an optimized and proprietary rFVIIa molecule, termed CT-001, for the safe and effective pharmaceutical intervention for the treatment of acute bleeding.